T Cell-Mediated Clearance of JHMV from the Central Nervous System

  • J. Williamson
  • S. Kyuwa
  • F.-I. Wang
  • S. Stohlman
Conference paper
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 276)


Infection with the JHM strain of mouse hepatitis virus (JHMV) results in acute encephalomyelitis accompanied by primary demyelination in the central nervous system (CNS; 1) . Animals that survive show evidence of persistent viral infection in the CNS that is associated with ongoing demyelination (2). Infection of immunocompromised animals suggests that the immune response is important not only in survival, but also as a determinant of whether the infection is cleared or progresses to become persistent. We initially demonstrated that the addition of anti-viral antibody to in vitro cultures of cells persistently infected with JHMV stopped the release of infectious virus (3,4). These in vitro data suggested that anti-viral antibody might play an important role in the ability of JHMV to establish a persistent infection in the CNS. Subsequent work has demonstrated that the passive transfer of monoclonal antibodies specific for all three structural proteins prevents death due to acute infection (5,6,7,8). Two very surprising findings were made. First, none of the transferred antibodies inhibited the replication of the virus in the CNS.


Mouse Hepatitis Virus Nylon Wool Antiviral Antibody Murine Coronavirus Immunocompromised Animal 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Weiner, L.P. 1973. Pathogenesis of demyelination produced by mouse hepatitis virus (JHM virus). Arch. Neurol. 28: 298–303.PubMedCrossRefGoogle Scholar
  2. 2.
    Stohlman, S. A. and L. P. Weiner. 1981. Chronic central nervous system demyelination in mice after JHM virus infection. Neurology 31: 38–44.PubMedGoogle Scholar
  3. 3.
    Stohlman, S. A. and L. P. Weiner. 1978. Stability of mouse hepatitis virus (JHM strain) during chronic infection of neuroblastoma cells. Arch. Virol. 57:53–61.PubMedCrossRefGoogle Scholar
  4. 4.
    Stohlman, S. A., Sakaguchi, A. Y. and L. P. Weiner. 1979. Rescue of a positive stranded RNA virus from antigen negative neuroblastoma cells. Life Sci. 24:1029–1036.PubMedCrossRefGoogle Scholar
  5. 5.
    Buchmeier, M. J., Lewicki, H. A., Talbot, P. J., and R. L. Knobler. 1984. Mouse hepatitis virus-4 (strain JHM)-induced neurologic disease is modulated in vivo by monoclonal antibody. Virology 132: 261–270.PubMedCrossRefGoogle Scholar
  6. 6.
    Fleming, J. O., Shubin, R. A., Sussman, M. A., Casteel, N. and S. A. Stohlman. 1989. Monoclonal antibodies to the matrix (El) glycoprotein of mouse hepatitis virus protect mice from encephalitis. Virology 168: 162–167.PubMedCrossRefGoogle Scholar
  7. 7.
    Nakanaga, K., Yamanouchi, K. and K. Fujiwara. 1986. Protective effect of monoclonal antibodies on lethal mouse hepatitis infection in mice. J. Virol. 59: 168–171.PubMedGoogle Scholar
  8. 8.
    Wege, H., Dorries, R. and H. Wege. 1984. Hybridoma antibodies to the murine Coronavirus JHM: characterization of the epitopes on the peplomer glycoprotein (E2). J. Gen. Virol. 65: 1931–1942.PubMedCrossRefGoogle Scholar
  9. 9.
    Stohlman, S., Matsushima, G., Casteel, N. and L. Weiner. 1986. In vivo effects of coronavirus-specific T cell clones: DTH-inducer cells prevent a lethal infection but do not inhibit virus replication. J. Immunol. 136:3052–3056.PubMedGoogle Scholar
  10. 10.
    Erlich, S., Matsushima, G. and S. Stohlman. 1989. Studies on the mechanism of protection from acute viral encephalomyelitis by delayed-type hypersensitivity inducer T cell clones. J. Neurol. Sci. 90:203–216.PubMedCrossRefGoogle Scholar
  11. 11.
    Sussman, M., Shubin, R., Kyuwa, S. and S. Stohlman. 1989. T-cell-mediated clearance of mouse hepatitis virus strain JHM from the central nervous system. J. Virol. 63: 3051–3056.PubMedGoogle Scholar
  12. 12.
    Sussman, M., Kachuck, N., Allen, H. and S. Stohlman. Immune mediated clearance of JHM from the CNS. Adv. Exp. Biol. Med. 218: 399–410.1986Google Scholar
  13. 13.
    Wong, G., Barteltt, P., Clark-Lewis, I., Battye, F. and J.W. Schrader. 1984. Inducible expression of H-2 and La antigens on brain cells. Nature 310: 668–670.CrossRefGoogle Scholar
  14. 14.
    Main, E., Monos, D., and L. Lampson. 1988. IFN-treated neuroblastoma cells remain resistant to T cell-mediated allo-killing, and susceptible to non-MHC restricted cytotoxicity. J. Immunol. 141:2943–2950.PubMedGoogle Scholar
  15. 15.
    Oldstone, M., Blount, A., Southern, P. and P. Lampert. 1986. Cytoimmunotherapy for persistent virus infection: unique clearance pattern from the central nervous system. Nature 321:239–243.PubMedCrossRefGoogle Scholar
  16. 16.
    Ahmed, R., Jamieson, E. and D. Porter. 1987. Immune therapy of a persistent and disseminated viral infection. J. Virol. 61:3920–3929.Google Scholar

Copyright information

© Plenum Press, New York 1990

Authors and Affiliations

  • J. Williamson
    • 1
  • S. Kyuwa
    • 1
  • F.-I. Wang
    • 1
  • S. Stohlman
    • 1
  1. 1.Departments of Neurology and MicrobiologyUniversity of Southern California School of MedicineLos AngelesUSA

Personalised recommendations